Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | CNR2 | P34972 | 7/20 | 0.80 |
| ▸ | CNR1 | P21554 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870901 | 1.00 | TP53 (1.00) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 | |
| SCHEMBL13870899 | 0.90 | TP53 (0.81) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 | |
| SCHEMBL17479175 | 0.87 | CNR2 (0.83) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 | |
| SCHEMBL14485213 | 0.85 | CNR2 (1.00) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 | |
| SCHEMBL13532206 | 0.82 | TP53 (0.85) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 | |
| SCHEMBL13870931 | 0.81 | TP53 (0.98) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 | |
| SCHEMBL13870909 | 0.80 | TP53 (1.00) | TP53SMN1; SMN2MAPTMAPK1MEN1 | |
| SCHEMBL4719951 | 0.80 | SMN1; SMN2 (0.97) | TP53SMN1; SMN2L3MBTL1MAPK1CNR2 | |
| SCHEMBL1094755 | 0.80 | TP53 (1.00) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 | |
| SCHEMBL10144136 | 0.79 | TSHR (1.00) | TP53SMN1; SMN2MAPTTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153803-B2 | Compositions and methods for modulating sirtuin activity | THE GENERAL HOSPITAL CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153803-B2 | Compositions and methods for modulating sirtuin activity | THE GENERAL HOSPITAL CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090259044-A1 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090259044-A1 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| EP-2068875-A2 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | The General Hospital Corporation (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090069559-A1 | Compositions and methods for modulating sirtuin activity | THE GENERAL HOSPITAL CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069559-A1 | Compositions and methods for modulating sirtuin activity | THE GENERAL HOSPITAL CORPORATION | 2009-03-12 | — | — | US | disclosed |
| WO-2008011476-A2 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | THE GENERAL HOSPITAL CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021063-A1 | Compositions and methods for modulating sirtuin activity | THE GENERAL HOSPITAL CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069559-A1 | Compositions and methods for modulating sirtuin activity | SIRT2, SIRT1, SIRT3 | TP53 2701/4885SMN1; SMN2 151/4885MAPT 206/4885 |
| US-20090259044-A1 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | SIRT2, SIRT1, SIRT3 | TP53 2701/4885SMN1; SMN2 151/4885MAPT 206/4885 |
| US-20080021063-A1 | Compositions and methods for modulating sirtuin activity | SIRT2, SIRT1, SIRT3 | TP53 2701/4885SMN1; SMN2 151/4885MAPT 206/4885 |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | NR1H2, NR1H3, HRH2 | TP53 4629/4885SMN1; SMN2 1572/4885MAPT 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.